PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its Q4 and full year 2020 financial results on February 10, 2021, before U.S. markets open. The company will hold a conference call at 8:30 AM ET to discuss the results and operational updates. PolyPid focuses on improving surgical outcomes with its proprietary PLEX technology that allows for targeted, prolonged-release therapeutics. Its lead product, D-PLEX100, is in Phase 3 trials for preventing surgical site infections.
- PolyPid's lead product, D-PLEX100, is in Phase 3 clinical trials for preventing surgical site infections, indicating potential for future revenue growth.
- None.
PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, February 10, 2021 | |
| Time: | 8:30 AM Eastern Time | |
| United States: | +1 877 870 9135 | |
| Israel: | +972 1809 213-985 | |
| International: | +44 (0) 2071 928338 | |
| Conference ID: | 1468387 | |
| Webcast: | https://edge.media-server.com/mmc/p/cx5so6fj |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Forward-looking Statements
This press release contains projections and other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
FAQ
When will PolyPid report its Q4 2020 financial results?
What time is PolyPid's conference call on February 10, 2021?
What is PolyPid's lead product candidate?
What technology does PolyPid use for its therapeutics?
Where can I access the webcast of PolyPid's conference call?
